Chief Financial Officer
Title: Chief Financial Officer.
Education: Degree of Bachelor of Science in Accounting and Finance.
Background: Over 20 years of experience in finance. Former CFO at O'Learys Trademark AB. Prior to that, Interim CFO at Rebtel and Head of Business Control at ICA Sverige AB. Before that held leading positions at Scan AB and SkiStar AB. Experience of working in listed-, private equity- and private companies. Board member of PMD Device Solutions AB.
Shares in Medivir: 21,000 class B
Warrants in Medivir: 322,500
VP Clinical Development
Title: VP Clinical Development
Education: PhD in Clinical Neuroscience, Karolinska Institutet. MSc in Molecular Biology, Stockholm University.
Background: More than 15 years’ experience of clinical development from large and small pharma such as Sedana Medical, Affibody and Astra Zeneca, as well as from academic innovation platforms. Has led development projects for biologics, small molecules and medical device within several therapeutic areas. More than 20 years’ experience of project- and portfolio management.
Shares in Medivir: 0.
Warrants in Medivir: 65,000.
Chief Executive Officer
Title: Chief Executive Officer
Education: Bachelor of Science in Business Administration
Background: 25 years of experience from pharmaceutical industry spanning global and local responsibilities. Has led product strategy development for late stage compounds preparing for regulatory approval and commercialisation as well as execution of launch for multiple compounds in specialty care. Primary area of focus in the past 10 years in the field of Oncology. Experience also includes interim CEO role for Sedana Medical AB and Director Investor Relations at AstraZeneca.
Shares in Medivir: 25,000 class B.
Warrants in Medivir: 490,000.
Interim Chief Medical Officer
Title: Interim Chief Medical Officer
Education: BSc in Physiology from the University of Wales, medical degrees from the University of Wales College of Medicine and Master of Laws degree from Cardiff Law School.
Background: More than 20 years of experience within drug development, mostly in oncology. Previously at Medeval Ltd and more recently at AstraZeneca. He has overseen the clinical development of several global drug programs, interacting with regulatory agencies, external clinical experts and academic groups worldwide. Fellow and former Board member of The Faculty of Pharmaceutical Medicine, and previously chair of its Ethical Issues committee and a member of its Professional Standards Committee.
Shares in Medivir: 0
Warrants in Medivir: 0
Chief Scientific Officer
Title: Chief Scientific Officer
Education: PhD in Medical Science at Uppsala University
Background: More than 25 years of experience in cancer research. During the last 10 years focused on industrial drug discovery and development projects in oncology. Prior to that he managed an academic research group as principal investigator, and has initiated several innovative scientific projects in cancer biology. He has published more than 50 scientific articles and holds several patents. Adjunct professor at the Medical Faculty of Uppsala University.
Shares in Medivir: 69,172 class B
Warrants in Medivir: 257,500
Chairman of the Board
Born: 1950 Title: Member of the Board since 2018, Chairman of the Board since 2021. Former CEO of Medivir AB.
Education: PhD at Uppsala University.
Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its development from a private start-up to a public, multibillion dollar company. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.
Other directorships: Chairman of the Board of Annexin Pharmaceuticals AB. Member of the Boards of Active Biotech, InDex Pharmaceuticals AB and SynAct Pharma AB.
Shares in Medivir: 350,000 class B shares.
Member of the Board
Born: 1956 Title: Member of the Board since 2018.
Education: Ph.D. in Genetics from Umeå University.
Background: Extensive experience of pharmaceutical and commercial development in senior positions with both biotech and pharmaceutical companies, such as KabiGen AB, Symbicom AB, AstraZeneca, and Biovitrum AB, and as CEO of Arexis AB. Responsible for Industrifonden’s life science operations from 2008 to 2016. He has held seats on the Boards of over 30 companies and is also a co-founder of two pharmaceutical development companies.
Other directorships: Member of the Board of InDex Pharmaceuticals AB. Chairman of the Boards of Cinclus Pharma Holding AB, Ignitus AB and Sixera Pharma AB.
Shares in Medivir: 20,000 class B shares.
Title: Member of the Board since 2022.
Education: Degree of Bachelor of Science in Accounting and Finance from Gothenburg University.
Background: Anette is currently CFO of XBrane Biopharma AB. She has a solid background in auditing with former operational assignments in Astrazeneca, Getinge and Sobi.
Other directorships: Chairperson of the Board of Nanolyze AB.
Born: 1979. Title: Member of the Board since 2021.
Education: Ph.D. Medical Sciences, Karolinska Institutet.
Background: CFO at Egetis Therapeutics AB. Former CFO at PledPharma and among others responsible for the listing of the company at Nasdaq Stockholm Main Market and former CEO at Medivir AB. Prior to that Investment Manager & Controller at Industrifonden and healthcare analyst at Pareto Securities and Öhman Fondkommission. Started his career as a researcher at Karolinska Institutet and later at the pharmaceutical companies Biolipox and Orexo.
Other directorships: Board member of Mahshid Advisors.
Shares in Medivir: 25,000.
Warrants in Medivir: 300,000.
Born: 1945. Title: Member of the Board since 2017.
Education: Professor of Tumour Biology at Uppsala University, the Faculty of Medicine, since 1986.
Background: Dean of the Faculty of Medicine at Uppsala University, 1996-2002, and Vice-Rector of Medicine and Pharmacy, 1999-2002. Chairman of the research board of the Swedish Cancer Society, 2003-2013. He has published over 300 papers in scientific journals, primarily on the mechanisms governing the uncontrolled growth of cancer cells. Member of the Royal Swedish Academy of Sciences, the European Molecular Biology Organisation, and the European Academy of Cancer Sciences.
Other directorships: Member of the Board of Hamlet Pharma AB and several advisory groups for medical research financing.
Shares in Medivir: 16,000 class B shares.